老年HPV阳性口咽鳞癌经口手术的多中心结局分析
这项多中心回顾性研究分析了75例70岁及以上HPV相关口咽鳞癌患者接受经口手术的结局。中位随访35.7个月时,3年总生存率为81.5%,疾病特异性生存率为94.3%。晚期cT分期与总生存下降独立相关,但老年患者整体生存良好,不应仅因年龄排除经口手术。
要点
- 70岁及以上HPV阳性口咽鳞癌患者经口手术后3年总生存率81.5%,疾病特异性生存率94.3%。
- 晚期cT分期(比值比2.74,95%CI 1.13-6.64)与总生存下降相关。
- 年龄大于80岁、严重合并症及cT3-4期患者生存更差,但不应仅因年龄排除手术。
核心结论
- 老年HPV相关口咽鳞癌患者接受经口手术可获得良好生存,不应仅基于年龄将其排除在此类治疗之外。
主要发现
- 中位随访35.7个月时,3年总生存率为81.5%,疾病特异性生存率为94.3%。
- 晚期cT分期与总生存下降独立相关(比值比2.74,95%CI 1.13-6.64)。
- 年龄大于80岁、严重合并症及cT3-4期患者生存更差。
关键数值与推荐
- 年龄大于80岁、严重合并症及cT3-4期被用于构建分期系统以区分生存更差的患者。
临床怎么用
- 对70岁及以上HPV相关口咽鳞癌患者,经口手术是可考虑的治疗选择,不应仅因年龄而排除。
局限性
- 回顾性研究设计,仅纳入两机构患者,样本量75例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) is rising, even in elderly patients. The outcomes of transoral surgery (TOS) in this population are not entirely known. METHODS: A retrospective review was performed at two institutions from October 2003 to September 2016 on patients 70 years or older with HPV-related OPSCC treated with TOS. RESULTS: A total of 75 patients were included with a mean age of 74 years (70-87 years). At a median follow-up of 35.7 months, 3-year overall survival was 81.5% and disease-specific survival was 94.3%. Advanced cT stage (odds ratio, 2.74; 95% confidence interval, 1.13-6.64) negatively impacted OS. Conjunctive consolidation was performed to create a staging system with patients older than 80 years, severe comorbidity, and cT3-4 having worse survival. CONCLUSIONS: Elderly patients with HPV-related OPSCC treated with TOS have excellent survival and therefore should not be excluded from such therapy based on age alone.
引用
- Jackson RS, Chen S, Last A, et al. Multi-institutional analysis of outcomes following transoral surgery for HPV-positive oropharyngeal squamous cell carcinoma in elderly patients. Head Neck. 2019. PMID: 31460691. doi:10.1002/hed.25946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。